The Relative Strength of C-Reactive Protein and Lipid Levels as Determinants of Ischemic Stroke Compared With Coronary Heart Disease in Women

Journal of the American College of Cardiology

Volumn 48, Issue 11, 2006, Pages 2235-2242

  Everett, Brendan M ^a,b   Kurth, Tobias ^a,c   Buring, Julie E ^a,c   Ridker, Paul M ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HAZARD ASSESSMENT; HUMAN; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING;

EID: 33845217662     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.09.030     Document Type: Article

References (45)

1. Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., and Hennekens C.H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 325 (1991) 373-381
2. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
3. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
4. Sharrett A.R., Ballantyne C.M., Coady S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 104 (2001) 1108-1113
5. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
6. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109 (2004) 837-842
7. Koenig W., Lowel H., Baumert J., and Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 109 (2004) 1349-1353
8. Pai J.K., Pischon T., Ma J., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351 (2004) 2599-2610
9. Welin L., Svardsudd K., Wilhelmsen L., Larsson B., and Tibblin G. Analysis of risk factors for stroke in a cohort of men born in 1913. N Engl J Med 317 (1987) 521-526
10. Harmsen P., Rosengren A., Tsipogianni A., and Wilhelmsen L. Risk factors for stroke in middle-aged men in Goteborg, Sweden. Stroke 21 (1990) 223-229
11. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 346 (1995) 1647-1653
12. Rastenyte D., Tuomilehto J., Domarkiene S., Cepaitis Z., and Reklaitiene R. Risk factors for death from stroke in middle-aged Lithuanian men: results from a 20-year prospective study. Stroke 27 (1996) 672-676
13. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 352 (1998) 1801-1807
14. Shahar E., Chambless L.E., Rosamond W.D., et al. Plasma lipid profile and incident ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) study. Stroke 34 (2003) 623-631
15. Bowman T.S., Sesso H.D., Ma J., et al. Cholesterol and the risk of ischemic stroke. Stroke 34 (2003) 2930-2934
16. Rost N.S., Wolf P.A., Kase C.S., et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 32 (2001) 2575-2579
17. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 165 (2005) 2479-2484
18. Wilhelmsen L., Svardsudd K., Korsan-Bengtsen K., et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311 (1984) 501-505
19. Grau A.J., Boddy A.W., Dukovic D.A., et al. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 35 (2004) 1147-1152
20. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
21. Atiya M., Kurth T., Berger K., Buring J.E., and Kase C.S. Interobserver agreement in the classification of stroke in the Women's Health Study. Stroke 34 (2003) 565-567
22. Rifai N., and King M.E. Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum. Clin Chem 32 (1986) 957-961
23. Roberts W.L., Moulton L., Law T.C., et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 47 (2001) 418-425
24. In: Hainline A., Karon J., and Lippel K. (Eds). Manual of Laboratory Operations: Lipid Research Clinics Program and Lipid and Lipoprotein Analysis. 2nd ed. (1982), Dept. of Health and Human Services, Bethesda, MD
25. Walsh B.W., Schiff I., Rosner B., et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325 (1991) 1196-1204
26. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 273 (1995) 199-208
27. Ridker P.M., Hennekens C.H., Rifai N., Buring J.E., and Manson J.E. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100 (1999) 713-716
28. Ridker P.M., Rifai N., Cook N.R., Bradwin G., and Buring J.E. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294 (2005) 326-333
29. Wendel-Vos G.C., Schuit A.J., Feskens E.J., et al. Physical activity and stroke. A meta-analysis of observational data. Int J Epidemiol 33 (2004) 787-798
30. Berger K., Ajani U.A., Kase C.S., et al. Light-to-moderate alcohol consumption and risk of stroke among U.S. male physicians. N Engl J Med 341 (1999) 1557-1564
31. Gaziano J.M., Buring J.E., Breslow J.L., et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 329 (1993) 1829-1834
32. Sagiv M., and Goldbourt U. Influence of physical work on high density lipoprotein cholesterol: implications for the risk of coronary heart disease. Int J Sports Med 15 (1994) 261-266
33. Tirschwell D.L., Smith N.L., Heckbert S.R., et al. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 63 (2004) 1868-1875
34. Iso H., Jacobs Jr. D.R., Wentworth D., Neaton J.D., and Cohen J.D. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 320 (1989) 904-910
35. Haheim L., Holme I., Hjermann I., and Leren P. Risk factors of stroke incidence and mortality. A 12-year follow-up of the Oslo Study. Stroke 24 (1993) 1484-1489
36. Pedro-Botet J., Senti M., Nogues X., et al. Lipoprotein and apolipoprotein profile in men with ischemic stroke. Role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke 23 (1992) 1556-1562
37. Benfante R., Yano K., Hwang L.J., et al. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk. Stroke 25 (1994) 814-820
38. Ebrahim S., Sung J., Song Y.M., et al. Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study. BMJ 333 (2006) 22-27
39. Sacco R.L., Benson R.T., Kargman D.E., et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke study. JAMA 285 (2001) 2729-2735
40. Chung M.K., Martin D.O., Sprecher D., et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104 (2001) 2886-2891
41. Aviles R.J., Martin D.O., Apperson-Hansen C., et al. Inflammation as a risk factor for atrial fibrillation. Circulation 108 (2003) 3006-3010
42. Iribarren C., Luepker R.V., McGovern P.G., Arnett D.K., and Blackburn H. Twelve-year trends in cardiovascular disease risk factors in the Minnesota Heart Survey. Are socioeconomic differences widening?. Arch Intern Med 157 (1997) 873-881
43. Humphrey L.L., Chan B.K., and Sox H.C. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 137 (2002) 273-284
44. Haas J.S., Kaplan C.P., Gerstenberger E.P., and Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140 (2004) 184-188
45. Hersh A.L., Stefanick M.L., and Stafford R.S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291 (2004) 47-53